Evogliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Evogliptin · Suganon
Marketed by Dong-A ST and partners
NCT02949193 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.
Reported efficacy
Change from baseline in HbA1c (%) After 24 weeks: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) (met)
Result source: NCT04170998
Sitagliptin · Januvia
Marketed by Merck & Co. and partners
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)
Result source: NCT00086502
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Evogliptin | Sitagliptin |
|---|---|---|
| HbA1c, change | -0.2% vs 0.1%a−0.3 vs placeboNCT029465412 other results
| -0.6% vs 0.2%−0.8 vs placeboNCT000875167 other results
|
| Body weight, change (kg) | —Not posted · NCT02949193 | -0.5 vs -1.4vs Oral SemaglutideNCT040178321 other result
|
| HbA1c below 7% | —Not posted · NCT02949193 | 49.5% vs 36.8%+12.7 vs placeboNCT014856144 other results
|
| Fasting plasma glucose, change | —Not posted · NCT02949193 | -0.7 vs 0.3−0.9 vs placeboNCT000875167 other results
|
| 3-point MACE (% with event) | —Not posted · NCT02949193 | —Not posted · NCT01529541 |
HbA1c, change
- Evogliptin
- -0.2% vs 0.1%a−0.3 vs placeboNCT02946541
2 other results
- -0.6% vs -0.0% NCT04170998
- -0.6% vs -0.7% NCT02949193
- Sitagliptin
- -0.6% vs 0.2%−0.8 vs placeboNCT00087516
7 other results
- -0.8% vs -0.1% NCT00086502
- -0.8% vs 0.2% NCT00087516
- -0.0% vs 0.2% NCT01485614
- -1.1% vs -0.7% NCT02791490
- -0.1% vs -1.0% NCT01485614
- -0.2% vs -0.7% NCT01485614
- -0.5% vs -1.1% NCT01907854
Body weight, change (kg)
- Evogliptin
- —Not posted · NCT02949193
- Sitagliptin
- -0.5 vs -1.4vs Oral SemaglutideNCT04017832
1 other result
- -1.8 vs -3.3 NCT01907854
HbA1c below 7%
- Evogliptin
- —Not posted · NCT02949193
- Sitagliptin
- 49.5% vs 36.8%+12.7 vs placeboNCT01485614
4 other results
- 28.8% vs 16.6% NCT02791490
- 15.6% vs 5.7% NCT02791490
- 28.4% vs 33.3% NCT01485614
- 49.5% vs 77.8% NCT01485614
Fasting plasma glucose, change
- Evogliptin
- —Not posted · NCT02949193
- Sitagliptin
- -0.7 vs 0.3−0.9 vs placeboNCT00087516
7 other results
- -0.9 vs 0.1 NCT00086502
- -0.9 vs 0.3 NCT00087516
- 0.4 vs 0.3 NCT01485614
- -1.6 vs -0.9 NCT02791490
- -0.5 vs -1.0 NCT04017832
- -0.2 vs -1.7 NCT01485614
- 0.6 vs -1.1 NCT01485614
3-point MACE (% with event)
- Evogliptin
- —Not posted · NCT02949193
- Sitagliptin
- —Not posted · NCT01529541
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Evogliptin: 1 of 5 rows · Sitagliptin: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Evogliptin Rows use multiple source trials | Sitagliptin Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.65% @ 24wka,b,c NCT04170998 · Phase 3 · sponsor-reported, not registry data | -1.27% (n=183) @ 24wkd,a,b,c NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-1.51% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.15% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | — | 74.6%100 mge NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results67.6%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 69.1%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 67.6%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 9% NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 12.9%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 3% NCT01131182 · Phase 4 · registry result, not featured evidence 20.5%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 10.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence 2.5%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1% NCT01485614 · Phase 3 · registry result, not featured evidence 4.8%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 10.6%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.6% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | — | 2.3%100 mge NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results4.2%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence — NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT02318693 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence —Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination — NCT01131182 · Phase 4 · registry result, not featured evidence 7.9%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 3.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination — NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence —100 mg NCT04017832 · Phase 3 · registry result, not featured evidence — NCT01485614 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 0.5% NCT03115112 · Phase 3 · registry result, not featured evidence — NCT02791490 · Phase 3 · registry result, not featured evidence |
| Serious AEs | — | 7.7%100 mge NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results10.1%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 80% NCT02556918 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence 0%Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence 0%Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination 0% NCT02256189 · Phase 4 · registry result, not featured evidence 0% NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 3.4% NCT01907854 · Phase 4 · registry result, not featured evidence 2% NCT01686932 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 3.7%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0% NCT01131182 · Phase 4 · registry result, not featured evidence 3.1%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 4.7%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 0% NCT00686634 · Phase 4 · registry result, not featured evidence 2.7% NCT00729326 · Phase 4 · registry result, not featured evidence 4.2%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 10.5% NCT01485614 · Phase 3 · registry result, not featured evidence 6.5%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 6.7%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.1% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — | 100 mge upper respiratory tract infection 13.1% dizziness 11.5% nasopharyngitis 9.2% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 30 more results100 mg/100 mg upper respiratory tract infection 15.1% dizziness 10.5% nasopharyngitis 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg upper respiratory tract infection 11.4% arthralgia 9.8% blood glucose increased 8.9% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg/200 mg upper respiratory tract infection 16.4% dizziness 12.4% influenza 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 infection 2% (placebo 2%) headache 1% (placebo 1%) loss of appetite 1% (placebo 0%) NCT02556918 · Phase 4 · registry result, not featured evidence 100 mg headache 1.6% hypertension 1.6% diarrhoea 0% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 15.8% arrhythmic events 5.3% genital infection 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence light-headedness 7.7% (placebo 7.7%) paresthesias 7.7% (placebo 0%) nausea 0% (placebo 7.7%) NCT02639637 · Phase 4 · registry result, not featured evidence light-headedness 0% (placebo 7.7%) nausea 0% (placebo 7.7%) paresthesias 0% (placebo 0%) NCT02639637 · Phase 4 · registry result, not featured evidence · combination rash 0% (placebo 2.8%) NCT01859793 · Phase 4 · registry result, not featured evidence hypoglycemia 0% NCT02312063 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination 50 mg erythema 38.5% hypoglycaemia 7.7% periodontitis 7.7% NCT02318693 · Phase 4 · registry result, not featured evidence diarrhoea 9.3% nausea 7.8% upper respiratory tract infection 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence hypoglycaemia 14% blood glucose decreased 6% NCT01686932 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination hyperglycemia 11.1% pressure ulcer/skin ulcer 11.1% hypoglycemia 3.7% NCT01378117 · Phase 4 · registry result, not featured evidence · combination hypoglycemia 6.9% pneumonia 6.9% urinary tract infection 6.9% NCT01378117 · Phase 4 · registry result, not featured evidence · combination headache 4.9% dizziness 3.9% hyperhidrosis 3.7% NCT01131182 · Phase 4 · registry result, not featured evidence nausea 15.7% vomiting 10.2% nasopharyngitis 8.7% NCT00870194 · Phase 4 · registry result, not featured evidence nausea 10.2% nasopharyngitis 7.8% headache 7% NCT00870194 · Phase 4 · registry result, not featured evidence · combination nausea 37% vomiting 20.5% headache 12.3% NCT00729326 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 7.8% diarrhoea 4.5% nausea 3.9% NCT04017832 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.8% nasopharyngitis 15.8% upper respiratory tract infection 12.6% NCT01485614 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.1% upper respiratory tract infection 14.5% diarrhoea 11.3% NCT01760447 · Phase 3 · registry result, not featured evidence hypoglycaemia 20% upper respiratory tract infection 11.1% abdominal pain 8.9% NCT01760447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13% hypoglycemia 5.2% influenza 5.2% NCT03115112 · Phase 3 · registry result, not featured evidence diarrhoea 7.9% (placebo 4.8%) NCT02791490 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 33 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sitagliptin
show 7 more results
show 3 more results
show 7 more results
show 3 more results
show 1 more result
show 2 more results
show 1 more result
+ 73 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evogliptin's landscape · Sitagliptin's landscape